EU approves FIAsp for the treatment of diabetes in adolescents and children

Novo Nordisk has announced that the European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above). This complements the previous indication, which covered adults only.

For this paediatric population, it is recommended that Fiasp is administered prior to the meal (0-2 minutes before the start of the meal). However, Fiasp can also be administered up to 20 minutes after the start of a meal (post-meal dosing) in situations when there is uncertainty about the meal intake. Close monitoring of blood sugar levels is advised when dosing Fiasp post-meal at dinner time to avoid nocturnal hypoglycaemia (low blood sugar levels).